BioCentury
ARTICLE | Company News

SciClone buys Chinese rights to Vibativ

May 28, 2015 1:47 AM UTC

Theravance Biopharma Inc. (NASDAQ:TBPH) granted SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) exclusive rights to the antibiotic Vibativ telavancin in China, Hong Kong, Macau, Taiwan and Vietnam. Theravance is eligible to receive $6 million, including upfront and milestone payments. SciClone will be responsible for development and commercialization costs.

Theravance expects SciClone to begin a Phase III trial in China once a clinical trial authorization (CTA) is approved. SciClone may pursue accelerated approval in China, where overprescription of antibiotics has led to issues with resistance. ...